ASX - By Stock
|
IMM |
Re:
Ann: Excellent initial Overall Survival Benefit in 1st line NSCLC
|
|
Vivo
|
27 |
15K |
18 |
18/05/23 |
18/05/23 |
ASX - By Stock
|
27
|
15K
|
18
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Vivo
|
2.7K |
1.1M |
8 |
18/05/23 |
18/05/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
8
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Excellent initial Overall Survival Benefit in 1st line NSCLC
|
|
Vivo
|
27 |
15K |
0 |
17/05/23 |
17/05/23 |
ASX - By Stock
|
27
|
15K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
CHM board Please delist from asx and transfer to US
|
|
Vivo
|
5 |
2.6K |
2 |
15/05/23 |
15/05/23 |
ASX - By Stock
|
5
|
2.6K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
How's the Capital Raise Going to Work?
|
|
Vivo
|
138 |
45K |
13 |
12/05/23 |
12/05/23 |
ASX - By Stock
|
138
|
45K
|
13
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Change of Director's Interest Notice - R Howard
|
|
Vivo
|
13 |
5.2K |
20 |
02/05/23 |
02/05/23 |
ASX - By Stock
|
13
|
5.2K
|
20
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Approval to start Efti & Bavencio trial in urothelial cancer
|
|
Vivo
|
7 |
3.6K |
5 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
7
|
3.6K
|
5
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep appoints Dr Florian Vogl as Chief Medical Officer
|
|
Vivo
|
3 |
1.9K |
4 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
3
|
1.9K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Vivo
|
2.7K |
1.1M |
3 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity Receives $6.7 million R&D Tax Incentive Refund
|
|
Vivo
|
7 |
3.1K |
3 |
19/04/23 |
19/04/23 |
ASX - By Stock
|
7
|
3.1K
|
3
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Vivo
|
743 |
339K |
13 |
19/04/23 |
19/04/23 |
ASX - By Stock
|
743
|
339K
|
13
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Vivo
|
743 |
339K |
2 |
19/04/23 |
19/04/23 |
ASX - By Stock
|
743
|
339K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Response to ASX Aware Query
|
|
Vivo
|
13 |
5.6K |
8 |
18/04/23 |
18/04/23 |
ASX - By Stock
|
13
|
5.6K
|
8
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma
|
|
Vivo
|
11 |
5.4K |
6 |
17/04/23 |
17/04/23 |
ASX - By Stock
|
11
|
5.4K
|
6
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Announces Changes to the Board
|
|
Vivo
|
11 |
7.4K |
5 |
12/04/23 |
12/04/23 |
ASX - By Stock
|
11
|
7.4K
|
5
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep Announces Changes to the Board
|
|
Vivo
|
11 |
7.4K |
17 |
11/04/23 |
11/04/23 |
ASX - By Stock
|
11
|
7.4K
|
17
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Vivo
|
2.7K |
1.1M |
14 |
02/04/23 |
02/04/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
14
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Vivo
|
2.7K |
1.1M |
3 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
3
|
|
ASX - By Stock
|
IMM |
Re:
Further Development
|
|
Vivo
|
15 |
11K |
1 |
27/03/23 |
27/03/23 |
ASX - By Stock
|
15
|
11K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Vivo
|
2.7K |
1.1M |
8 |
27/03/23 |
27/03/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
8
|
|
ASX - By Stock
|
CHM |
Re:
How's the Capital Raise Going to Work?
|
|
Vivo
|
138 |
45K |
1 |
17/03/23 |
17/03/23 |
ASX - By Stock
|
138
|
45K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Initiation of Ph 2/3 Trial for Metastatic Breast Cancer
|
|
Vivo
|
9 |
6.1K |
2 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
9
|
6.1K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: World leading expert in copper-67 joins Clarity SAB
|
|
Vivo
|
5 |
2.4K |
1 |
10/03/23 |
10/03/23 |
ASX - By Stock
|
5
|
2.4K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Vivo
|
2.7K |
1.1M |
5 |
06/03/23 |
06/03/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
5
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Vivo
|
2.7K |
1.1M |
7 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
7
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Business Update Presentation
|
|
Vivo
|
43 |
13K |
1 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
43
|
13K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
Vivo
|
128 |
771K |
2 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
128
|
771K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Overnight Market report
|
|
Vivo
|
2.7K |
1.1M |
0 |
26/02/23 |
26/02/23 |
ASX - By Stock
|
2.7K
|
1.1M
|
0
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
Vivo
|
128 |
771K |
2 |
25/02/23 |
25/02/23 |
ASX - By Stock
|
128
|
771K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
a current prediction
|
|
Vivo
|
128 |
771K |
13 |
23/02/23 |
23/02/23 |
ASX - By Stock
|
128
|
771K
|
13
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Vivo
|
29 |
13K |
3 |
09/05/22 |
09/05/22 |
ASX - By Stock
|
29
|
13K
|
3
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Vivo
|
29 |
13K |
9 |
08/05/22 |
08/05/22 |
ASX - By Stock
|
29
|
13K
|
9
|
|
ASX - By Stock
|
IMM |
Re:
Ann: New & significant data from AIPAC phase 2b trial in MBC
|
|
Vivo
|
37 |
18K |
15 |
05/05/22 |
05/05/22 |
ASX - By Stock
|
37
|
18K
|
15
|
|
ASX - By Stock
|
IMM |
Re:
Ann: New & significant data from AIPAC phase 2b trial in MBC
|
|
Vivo
|
37 |
18K |
28 |
05/05/22 |
05/05/22 |
ASX - By Stock
|
37
|
18K
|
28
|
|
ASX - By Stock
|
IMM |
Re:
Ann: New & significant data from AIPAC phase 2b trial in MBC
|
|
Vivo
|
37 |
18K |
18 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
37
|
18K
|
18
|
|
Charts
|
IMU Biotech |
Re:
IMUGENE CHART. TA only
|
|
Vivo
|
33K |
16M |
10 |
04/05/22 |
04/05/22 |
Charts
|
33K
|
16M
|
10
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Vivo
|
382 |
194K |
2 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
382
|
194K
|
2
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Vivo
|
382 |
194K |
0 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
382
|
194K
|
0
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Termination of Supply Agreement
|
|
Vivo
|
448 |
253K |
3 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
448
|
253K
|
3
|
|
Charts
|
IMU Biotech |
Re:
IMUGENE CHART. TA only
|
|
Vivo
|
33K |
16M |
1 |
02/05/22 |
02/05/22 |
Charts
|
33K
|
16M
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Vivo
|
382 |
194K |
15 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
382
|
194K
|
15
|
|
ASX - By Stock
|
IMM |
Re:
Media
|
|
Vivo
|
382 |
194K |
3 |
01/05/22 |
01/05/22 |
ASX - By Stock
|
382
|
194K
|
3
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep to announce new TACTI-002 data at ASCO 2022
|
|
Vivo
|
47 |
29K |
5 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
47
|
29K
|
5
|
|
ASX - By Stock
|
IMM |
Re:
IMM Chart
|
|
Vivo
|
19 |
9.9K |
4 |
21/03/22 |
21/03/22 |
ASX - By Stock
|
19
|
9.9K
|
4
|
|
ASX - By Stock
|
IMM |
Re:
IMM Chart
|
|
Vivo
|
19 |
9.9K |
1 |
21/03/22 |
21/03/22 |
ASX - By Stock
|
19
|
9.9K
|
1
|
|
ASX - By Stock
|
IMM |
Re:
Relatlimab
|
|
Vivo
|
33 |
18K |
8 |
20/03/22 |
20/03/22 |
ASX - By Stock
|
33
|
18K
|
8
|
|
ASX - By Stock
|
IMM |
Re:
Relatlimab
|
|
Vivo
|
33 |
18K |
5 |
20/03/22 |
20/03/22 |
ASX - By Stock
|
33
|
18K
|
5
|
|
ASX - By Stock
|
IMM |
Re:
IMM Chart
|
|
Vivo
|
19 |
9.9K |
8 |
19/03/22 |
19/03/22 |
ASX - By Stock
|
19
|
9.9K
|
8
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep to present Phase IIb breast cancer data at ESMO 2022
|
|
Vivo
|
18 |
9.2K |
6 |
18/03/22 |
18/03/22 |
ASX - By Stock
|
18
|
9.2K
|
6
|
|
ASX - By Stock
|
IMM |
Re:
Ann: Immutep to present Phase IIb breast cancer data at ESMO 2022
|
|
Vivo
|
18 |
9.2K |
1 |
18/03/22 |
18/03/22 |
ASX - By Stock
|
18
|
9.2K
|
1
|
|